High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

The management of R/M HNSCC is rapidly evolving with new available treatment molecules and combination modalities. Anti-EGFR cetuximab (CTX) and immune checkpoint inhibitors (ICI) can be used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluoro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauffert, Bruno, Zhou, Yuedan, Medjkoune, Liza, Ouikene, Abdenour, Galez, Agnes, Belkhir, Farid, Saint-Germain, Pierre, Youssef, Ali, Chehimi, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893993/
https://www.ncbi.nlm.nih.gov/pubmed/36743882
http://dx.doi.org/10.1159/000528326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893993/
https://www.ncbi.nlm.nih.gov/pubmed/36743882
http://dx.doi.org/10.1159/000528326

Ejemplares similares